glaucoma research foundation logo in black
Search
Generic filters
Filter by Categories
Eye Health
Personal Stories
Facts & Stats
Lifestyle Tips
Eye Exams
Treatments
Q&A
Research Updates
News
Search
Generic filters
Filter by Categories
Eye Health
Personal Stories
Facts & Stats
Lifestyle Tips
Eye Exams
Treatments
Q&A
Research Updates
News

FDA Approves New Biodegradable Glaucoma Implant from Allergan

Allergan has announced the approval of DURYSTA™ (bimatoprost implant), the first biodegradable sustained-release implant for the treatment of open-angle glaucoma

BACK TO BLOG HOME

The word NEWS is spelled out in blocks setting on top of an open newspaper
The word NEWS is spelled out in blocks setting on top of an open newspaper

FDA Approves New Biodegradable Glaucoma Implant from Allergan

Allergan has announced the approval of DURYSTA™ (bimatoprost implant), the first biodegradable sustained-release implant for the treatment of open-angle glaucoma

March 6, 2020 – Allergan announced today the approval of DURYSTA™ (bimatoprost implant), the first biodegradable sustained-release implant for the treatment of open-angle glaucoma.

The implant works by delivering 10 mcg of bimatoprost directly into the anterior chamber of the eye, although its use is limited to a single implant per eye. The FDA approval was based on the results of the two phase 3 ARTEMIS studies of Durysta, which evaluated the implant over 20 months, including an 8-month extended follow up.

“Millions of people are living with glaucoma, one of the leading causes of vision loss; however, new treatment options are needed to help doctors and patients better manage this disease,” said Felipe Medeiros, MD, PhD, Distinguished Professor of Ophthalmology and Vice Chair for Technology, Director Clinical Research Unit, Department of Ophthalmology, Duke University. “The ARTEMIS trials demonstrated that DURYSTA™ lowered IOP in patients by approximately 30 percent and demonstrated a duration of effect through the 12-week primary efficacy period. As the first FDA-approved intracameral, biodegradable sustained-release implant providing continuous drug delivery, DURYSTA™ has the potential to significantly shift the paradigm for treating glaucoma.”

“Today’s FDA approval marks a breakthrough milestone for the glaucoma community and provides a much-needed option for patients challenged with topical drops or needing alternative options,” said David Nicholson, Chief Research and Development Officer, Allergan.”

Source: Allergan Press Release

 

First posted on March 6, 2020; Reviewed on May 12, 2022

image_print
back of mailing envelope. snail mail icon.

Print Subscription

(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)

Name(Required)
Address(Required)
This field is for validation purposes and should be left unchanged.

You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.

folded paper airplane. email icon.

E-mail Subscription

Name
This field is for validation purposes and should be left unchanged.

You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.